News

Chugai Pharmaceutical Co Ltd announced that the results of the Japanese phase III study (J-ALEX) of Alecensa®, in ALK fusion gene positive NSCLC patients, will be presented at the annual meeting of the ASCO which will be held June...

Valeant Pharmaceuticals International, Inc. announced that Mr. Joseph Papa, Chairman and Chief Executive Officer, will participate at the UBS Global Healthcare Conference to be held at the Grand Hyatt Hotel in New York City on Monday, May 23, 2016...

First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna®both in front-line and second-line following Glivec®* First genomic analysis and 3-year efficacy/safety update for Tafinlar® + Mekinist® combination in BRAF V600E/K-mutant advanced melanoma,...

Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the community via social entrepreneurs, while digital health technology empowers patients...

Mallinckrodt plc a leading global specialty biopharmaceutical company confirmed enrollment of the first patient in the company's Phase 4 clinical study assessing the efficacy of H.P. Acthar® Gel (repository corticotropin injection) for inducing remission of proteinuria due to treatment-resistant...

Takeda Pharmaceutical Company Limited announced the appointment of James Kehoe as Takeda’s new Chief Financial Officer and Corporate Officer, effective on June 15, 2016. Mr. Kehoe will be based in Tokyo and reports directly to Christophe Weber, President &...

Shire plc will present new research on Binge Eating Disorder (B.E.D.) and Attention-Deficit/Hyperactivity Disorder (ADHD) at the upcoming 169th Annual Meeting of the American Psychiatric Association (APA) in Atlanta, GA, demonstrating its ongoing commitment to furthering the understanding and...